MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer

  1. Sohail F. Tavazoie1,8,9
  1. 1Laboratory of Systems Cancer Biology, Rockefeller University, New York, New York 10065, USA;
  2. 2Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA;
  3. 3Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA;
  4. 4Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA;
  5. 5Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA;
  6. 6Watson School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724, USA;
  7. 7Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    1. 8 These authors contributed equally to this work.

    Abstract

    Post-transcriptional regulators have emerged as robust effectors of metastasis and display deregulated expression through unknown mechanisms. Here, we reveal that the human microRNA-335 locus undergoes genetic deletion and epigenetic promoter hypermethylation in every metastatic derivative obtained from independent patients’ malignant cell populations. Genetic deletion of miR-335 is a common event in human breast cancer, is enriched for in breast cancer metastases, and also correlates with ovarian cancer recurrence. We furthermore identify miR-335 as a robust inhibitor of tumor reinitiation. We thus implicate the miR-335 locus on 7q32.2 as the first selective metastasis suppressor and tumor initiation suppressor locus in human breast cancer.

    Keywords

    Footnotes

    • Received July 24, 2010.
    • Accepted December 13, 2010.
    | Table of Contents

    Life Science Alliance